A data series of 274 patients with BRAF-mutated melanoma who sequentially received BRAF inhibitors and immunotherapy (high-dose IL-2, ipilimumab, or PD-1 inhibitors) illustrated that ipilimumab therapy after BRAF inhibitors was associated with no tumor response and poor survival [50]. The gene discussed is PDCD1; the disease is melanoma.